The B. multivorans had previously been susceptible to ceftazidime, but had been resistant to aztreonam in the 6 years prior to presentation, although it had been shown to be susceptible prior to that.
Sputum culture on admission to hospital produced a heavy growth of B. multivorans resistant to amikacin, aztreonam, ceftazidime, chloramphenicol, ciprofloxacin, colistin, gentamicin, meropenem, piperacillin/tazobactam and tobramycin. Scanty growths of P. aeruginosa (susceptible to ceftazidime and aztreonam) and Candida albicans were also identified. For the B. multivorans, the MIC of ceftazidime/avibactam was determined to be 2.0 mg/L by MIC test strip. Intravenous ceftazidime/avibactam at 2 g q8h plus aztreonam at 2 g q8h were commenced. The patient made rapid clinical improvement and suffered no adverse effects. After 2 weeks of therapy, the patient's FEV1 (forced expiratory volume in 1 s) improved from a baseline of 0.9 to 1.24 L (39% of predicted), achieving the best spirometric values for 3 years; in the 5 months since treatment the patient has not been readmitted to hospital.
We report the successful use of ceftazidime/avibactam, combined with aztreonam, in a CF patient with XDR B. multivorans infection. Papp-Wallace et al. 4 demonstrated that avibactam counteracts the effect of the class A carbapenemase PenA commonly produced by B. multivorans and thought to be an important mechanism of resistance to b-lactams. We hypothesize that this was the most likely mechanism of resistance to ceftazidime in our patient, although other mechanisms may have been relevant. Additionally, avibactam may also have increased the isolate's susceptibility to aztreonam, given the previous susceptibility, as demonstrated by Everaert and Coenye 5 in vitro for some bacteria of the Burkholderia cepacia complex. The action at different PBPs may also have been advantageous; ceftazidime has been shown to have affinity for PBP1a in Burkholderia cenocepacia and PBP1a and PBP3 in P. aeruginosa, and aztreonam has affinity for PBP3 in P. aeruginosa. [6] [7] [8] Avibactam also binds to PBP2 in E. coli. 9 It is also possible that, if overexpressed, two antibiotics acting at the same PBP may lead to saturation when monotherapy does not. 8 We fully acknowledge that the clinical response may have been due to ceftazidime/avibactam alone, but we rejected monotherapy because of concern about further resistance, as had already occurred in this patient. A subsequent B. multivorans isolate, ascertained 5 months after the above episode, had an MIC of ceftazidime/avibactam of 3 mg/L (by MIC test strip), but was resistant to the other agents mentioned above. Urgent clinical research to inform the selection of antibiotic regimens that maximize clinical efficacy while minimizing resistance in XDR bacteria is required.
Funding
This report was written as part of our routine work.
Transparency declarations
None to declare. 2 We here focus on the potential DDIs between ritonavir-or cobicistat-based antiretroviral regimens and calcium channel blockers (CCBs), which are widely used antihypertensive drugs. However, as they are mainly metabolized by cytochrome P450 3A (CYP3A) isoenzymes, whose activity is significantly inhibited by ritonavir or cobicistat, concomitant treatment with boosted antiretroviral regimens should be carefully monitored in clinical practice because of the high risk of side effects. 3 This retrospective, observational study considered all of our patients who had received ritonavir-or cobicistat-based regimens combined with CCBs for at least 6 months. The risk of DDIs due to the individual drug combinations was retrieved from the Liverpool website (www.hiv-druginteractions.org) and their clinical relevance was verified by assessing blood pressure (BP) after starting the combined therapy. BP is always measured during the course of each outpatient visit (scheduled every 4 months) by the attending physician and periodically monitored by the patients at home (the patients are asked to report any abnormal BP measurements at their next visit).
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Clinically relevant hypotension was defined as the presence of a significant drop in BP to ,90/60 mmHg, accompanied by at least one of the following symptoms: dizziness or lightheadedness, abnormal heart rhythm and the loss of consciousness. Moreover, in order to identify alterations in the PR interval, we used the patients' medical records to examine the electrocardiographic assessments made at least twice a year in hypertensive patients. The data are expressed as median values with IQRs. It was considered unnecessary to apply for Ethics Committee approval because, under Italian law, it is required only in the case of prospective clinical trials of medical products for clinical use (Articles 6 and 9 of Legislative Decree 211/2003); however, all of the patients gave their written informed consent to the medical procedures/interventions undertaken for routine clinical purposes.
Forty-four out of the 620 patients screened during the first 15 months of the GAP were being treated with CCBs (Table 1) : they had a median age of 65 years (IQR 59-73), were mainly male (84%) and Caucasians (95%) and had been receiving CCBs for a
